14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Molecular hybridization is a well-exploited medicinal chemistry strategy that aims to combine two molecules (or parts of them) in a new, single chemical entity. Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest. Hybrid compounds can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies. Although very promising to combat the multifactorial nature of complex diseases, the development of molecular hybrids faces the critical issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties. In this review, we present recent case histories from our own research group that demonstrate why and how molecular hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer’s and parasitic diseases. Selected examples spanning from linker- to fragment- based hybrids will allow to discuss issues and consequences relevant to drug design.

          Related collections

          Most cited references99

          • Record: found
          • Abstract: not found
          • Article: not found

          The combinatorial synthesis of bicyclic privileged structures or privileged substructures.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Multi-target-directed ligands to combat neurodegenerative diseases.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vemurafenib: the first drug approved for BRAF-mutant cancer.

              The identification of driver oncogenes has provided important targets for drugs that can change the landscape of cancer therapies. One such example is the BRAF oncogene, which is found in about half of all melanomas as well as several other cancers. As a druggable kinase, oncogenic BRAF has become a crucial target of small-molecule drug discovery efforts. Following a rapid clinical development path, vemurafenib (Zelboraf; Plexxikon/Roche) was approved for the treatment of BRAF-mutated metastatic melanoma in the United States in August 2011 and the European Union in February 2012. This Review describes the underlying biology of BRAF, the technology used to identify vemurafenib and its clinical development milestones, along with future prospects based on lessons learned during its development.
                Bookmark

                Author and article information

                Journal
                Current Topics in Medicinal Chemistry
                CTMC
                Bentham Science Publishers Ltd.
                15680266
                October 21 2019
                October 21 2019
                : 19
                : 19
                : 1694-1711
                Affiliations
                [1 ]Department of Pharmacy and Biotechnology, Alma Mater Studiorum − University of Bologna, I-40126, Bologna, Italy
                Article
                10.2174/1568026619666190619115735
                31237210
                b33c7fa5-85aa-4a7a-b548-cea126538f32
                © 2019
                History

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content135

                Cited by47

                Most referenced authors1,595